“Big money” Positions
In Q2 2018 Meridian Bioscience Inc (NASDAQ:VIVO) big money sentiment decreased to 1.19, SEC.gov filings reveal. So its down -0.43, from 2018Q1’s 1.62. 74 active investment managers opened new and increased positions, while 62 sold and decreased their holdings in Meridian Bioscience Inc so the sentiment turned negative. These funds own 36.43 million shares, that’s up from 36.20 million shares in 2018Q1. Funds holding Meridian Bioscience Inc in top 10 changed to 0 from 0 for the same number . 20 Investors Sold All; 42 Reduced Holdings; 53 increased stakes while 21 active investment managers bought stakes.
Significant Meridian Bioscience Inc Investors
Brown Capital Management Llc owns 3.66 million shares in Meridian Bioscience Inc as of Q2 2018. Meridian Bioscience Inc’s shareholder Piermont Capital Management Inc. owns 91,500 shares as of Q2 2018. Systematic Financial Management Lp reported 1.13 million shares. The Pennsylvania-based fund Connors Investor Services Inc have invested about 0.4% of the investment professional’s stock portfolio in Meridian Bioscience Inc. The North Carolina-based fund Verity Asset Management Inc. looks positive on Meridian Bioscience Inc, owning 27,338 shares.
Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.The firm is worth $836.04 million. The firm operates through Diagnostics and Life Science divisions.34.6 is the P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.
The stock increased 0.46% or $0.09 during the last trading session, reaching $19.72.Meridian Bioscience, Inc. is uptrending after having risen 11.66% since November 10, 2017. VIVO has 434,441 volume or 83.93% up from normal. VIVO underperformed the S&P 500 by 3.96%.
Moreover, Tiaa Cref Mngmt Limited Liability Co has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Ameritas Inv Prns holds 3,556 shs or 0% of its capital. Pnc Financial Services Gru Incorporated, Pennsylvania-based fund reported 115,480 shs. Teachers Retirement Systems Of The State Of Kentucky has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Us Bankshares De reported 0% stake. 170,072 are held by Hotchkis & Wiley Capital Lc. North Star Management has invested 0.1% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Louisiana State Employees Retirement System holds 0.01% or 19,000 shs. Ameriprise holds 0% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 364,931 shs. Ubs Asset Management Americas reported 23,210 shs. California State Teachers Retirement System owns 63,591 shs for 0% of their capital. Bluemountain Capital Mngmt Lc invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Hartford Mngmt Company invested in 16,639 shs. Prelude Capital Mngmt Ltd Limited Liability Company has 1,217 shs. Cornercap Invest Counsel Inc invested 0.06% of its capital in Meridian Bioscience, Inc. (NASDAQ:VIVO).
Meridian Bioscience, Inc. registered $31,250 net activity with 1 insider buy and 0 insider sales since August 24, 2018.
For more Meridian Bioscience, Inc. (NASDAQ:VIVO) news announced recently go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “80 Biggest Movers From Yesterday” announced on November 09, 2018, “Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018” on October 17, 2018, “Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate …” with a publish date: November 08, 2018, “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” and the last “Meridian Bioscience beats by $0.04, beats on revenue” with publication date: November 08, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.